Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr-Jun;18(2):181-186.
doi: 10.4183/aeb.2022.181.

EFFECTS OF THE GONADOTROPIN-RELEASING HORMONE AGONIST THERAPY ON GROWTH AND BODY MASS INDEX IN GIRLS WITH IDIOPATHIC CENTRAL PRECOCIOUS PUBERTY

Z Donbaloğlu  1 , A Bedel  1 , E Barsal Çetiner  1 , B Singin  1 , B Aydın Behram  1 , H Tuhan  1 , M Parlak  1
Affiliations

EFFECTS OF THE GONADOTROPIN-RELEASING HORMONE AGONIST THERAPY ON GROWTH AND BODY MASS INDEX IN GIRLS WITH IDIOPATHIC CENTRAL PRECOCIOUS PUBERTY

Z Donbaloğlu et al. Acta Endocrinol (Buchar). 2022 Apr-Jun.

Abstract

Objective: We aimed to examine the auxological findings of girls diagnosed with idiopathic central precocious puberty (CPP) at the end of the GnRHa treatment and to investigate the effect of related factors on the height gain of those patients.

Design: Single-center, descriptive, cross-sectional retrospective study.

Method: A total of 43 patients who were diagnosed with idiopathic CPP and treated with GnRHa between 2012 - 2021 were included in to the study.

Results: A decline in height standard deviation score (SDS) from 1.20 ± 0.14 to 1.02 ± 0.06 during the therapy was observed (P<0.001). The bone age/chronological age ratio was decreased and predictive adult height was increased at the end of the therapy (P<0.001; P=0.001). Both the rates of being overweight and obesity were increased (38.6% to 50% and 9% to 15.9%) when the treatment onset compared to the end of therapy. At the end of the treatment, the mean body mass index (BMI) SDS of the overweight patients was still higher compared to the normal-weight group (P<0.001).

Conclusion: We observed a positive effect of GnRHa therapy on height potential. An increase in BMI during the therapy has been also demonstrated especially in subjects who were overweight before treatment.

Keywords: Central precocious puberty; GnRH analog therapy; Growth; Obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Antoniazzi F, Zamboni G. Central precocious puberty: current treatment options. Paediatr Drugs. 2004;6(4):211–231. - PubMed
    1. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, ESPE-LWPES GnRH Analogs Consensus Conference Group. Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP, Coste J, Deal S, de Vries L, Foster C, Heger S, Holland J, Jahnukainen K, Juul A, Kaplowitz P, Lahlou N, Lee MM, Lee P, Merke DP, Neely EK, Oostdijk W, Phillip M, Rosenfield RL, Shulman D, Styne D, Tauber M, Wit JM. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752–762. - PubMed
    1. Crowley WF, Jr, Comite F, Vale W, Rivier J, Loriaux DL, Cutler GB., Jr Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab. 1981;52(2):370–372. - PubMed
    1. Neyzi O, Bundak R, Gökçay G, Günöz H, Furman A, Darendeliler F, Baş F. Reference Values for Weight, Height, Head Circumference, and Body Mass Index in Turkish Children. J Clin Res Pediatr Endocrinol. 2015;7(4):280–293. - PMC - PubMed
    1. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Archives of disease in childhood. 1969;44(235):291–303. - PMC - PubMed

LinkOut - more resources